Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03827837
Recruitment Status : Unknown
Verified January 2019 by Jiangsu HengRui Medicine Co., Ltd..
Recruitment status was:  Recruiting
First Posted : February 4, 2019
Last Update Posted : February 4, 2019
Information provided by (Responsible Party):
Jiangsu HengRui Medicine Co., Ltd.

Brief Summary:

Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase inhibitor Famitinib in subjects with advanced RCC/UC/CC/EC and recurrent OC.

chort1: Renal Cell Carcinoma (RCC) chort2: Urothelial Carcinoma(UC) chort3: Ovarian Cancer (OC) chort4: Cervical Cancer (CC) chort5: Endometrial Cancer (EC)

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Urothelial Carcinoma Cervical Cancer Ovarian Cancer Recurrent Endometrial Cancer Biological: SHR-1210 Drug: Famitinib Phase 2

Detailed Description:
Stage 1: Approximately 110 participants will be recruited, 22 participants per chort; Stage 2: Approximately 55 participants will be recruited, 11 participants per chort, if more than 7(including 7) patients reached ORR in every chort ; Approximately 155 participants will be recruited, 21 participants per chort, if 3 ≤ patients <7 patients reached ORR in every chort.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 265 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Famitinib Malate Plus Anti-PD1 Therapy (SHR-1210) in Advanced Renal Cell Carcinoma, Urothelial Carcinoma, Advanced Cervical Cancer, Relapse Ovarian Cancer, Endometrial Cancer: Multi-institutional, Open-label, Phase 2 Trial
Actual Study Start Date : January 23, 2019
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021

Arm Intervention/treatment
Experimental: SHR-1210 combined with Famitinb
SHR-1210 + Famitinib
Biological: SHR-1210
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Other Name: Camrelizumab

Drug: Famitinib
a small-molecule multikinase inhibitor
Other Name: Famitinib Malate Capsule

Primary Outcome Measures :
  1. Overall response rate (ORR) [ Time Frame: Up to 2 years ]
    Defined as complete or partial response per RECIST 1.1 criteria with assessment every 9 weeks

Secondary Outcome Measures :
  1. Duration of Response (DoR) [ Time Frame: Up to 2 years ]
    Duration of Response (DoR) per RECIST 1.1

  2. Disease Control Rate (DCR) [ Time Frame: Up to 2 years ]
    Disease Control Rate per RECIST 1.1

  3. Time to objective response(TTR) [ Time Frame: Up to 2 years ]
    Time to objective response per RECIST 1.1

  4. Progression-free survival(PFS) [ Time Frame: Up to 2 years ]
    Progression-free survival(PFS) per RECIST 1.1

  5. Overall survival(OS) [ Time Frame: Up to 2 years ]
    Overal Survial will be calculated based on Kaplan-Meier estimates

  6. 12-month survival rate [ Time Frame: Up to 1 year ]
    12-month survival rate will be calculated based on Kaplan-Meier estimates of Overall survival at 12 months

  7. number of participants who experience an adverse event (AE) [ Time Frame: From the first assignment of informed consent form up to 90 days after the last dose ]
    number of participants who experience an adverse event (AE) per CTCAE 4.03

  8. serum SHR-1210 concentrations [ Time Frame: From the first dose up to 30 days after the last dose ]
    serum SHR-1210 concentrations

  9. Positive rate of ADA [ Time Frame: From the first dose up to 30 days after the last dose ]
    Positive rate of anti-SHR1210 antibody

  10. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Day 1 of cycle 3 (each cycle is 21 days) ]
    Cmax, based PK parameters

  11. Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Day 1 of cycle 3 (each cycle is 21 days) ]
    Summarized by dose, cycle, day and time

  12. Apparent Oral Clearance (CL/F) [ Time Frame: Day 1 of cycle 3 (each cycle is 21 days) ]
    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Be willing and able to provide written informed consent/ for the trial.
  2. Be at least 18 years of age on day of signing informed consent, male or female.
  3. Patients with one of the following tumors:

    • Histologically or cytologically confirmed diagnosis of advanced renal cell carcinoma (defined as more than 50% clear cell component) after failure of IL-2 and/or anti-VEGF TKI treatment. If patients didn't want to use anti-VEGF TKI medicine or couldn't stand anti-VEGF TKI medicine costs, they will also be considered.
    • Histologically or cytologically confirmed diagnosis of unresectable urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra (defined as more than 50% transitional cell component) after failure of no more than two prior platinum-based chemotherapeutic regimen.
    • Histologically or cytologically confirmed diagnosis of advanced squamous cell carcinoma of the cervix after failure of first-line system treatment.
    • Histologically confirmed diagnosis of recurrent or refractory epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer that are relapsed and resistant (recurred less than 6 months after chemotherapy) or refractory (progressed on chemotherapy) to prior platinum-based standard care systemic regimen.
    • Histologically confirmed diagnosis of recurrent or refractory endometrial cancer that are relapsed and resistant or refractory (progressed on chemotherapy) to prior platinum-based standard care systemic regimen.
  4. At least one measurable lesion according to RECIST 1.1.
  5. The patients can swallow pills.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
  7. Life expectancy of at least 12 weeks.
  8. The results of patients' blood tests are as follows:-Neutrophils≥1.5E+9/L; - Plt≥90E+9/L; -Hb≥90g/L; -ALB≥30g/L ;-TSH≤1×ULN;-TBIL ≤ 1 ×ULN;-ALT and AST ≤ 3 ×ULN; AKP≤ 2.5×ULN; -Creatinine ≤ 1.5×ULN.
  9. Male or Female patient of childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake.

Exclusion Criteria:

  1. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
  2. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration.
  3. Known history of hypersensitivity to other antibody formulation.
  4. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 2 weeks prior to trial treatment.
  5. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents: systolic blood pressure ≥140 mmHg, diastolic blood pressure ≥ 90 mmHg.
  6. Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to(1)Congestive heart failure (New York heart association (NYHA) class > 2);(2)unstable or severe angina; (3)myocardial infarction within 12 months before enrollment;(4) ventricular arrhythmia which need medical intervention.(5)QTc>450ms(male)/QTc>470ms (female);
  7. Coagulation abnormalities (INR>2.0、PT>16s), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy.
  8. Bleeding history, having bleeding event(≥3 Grade according CTCAE 4.0 )within 4 weeks before screening.
  9. Tumor invasion around major vessels shown by imaging, high risk of major vascular invasion leading to massive hemorrhage judged by investigators.
  10. Previous Arterial/venous thrombosis events within 6 months.
  11. Known hereditary or acquired bleeding and thrombosis tendency.
  12. Proteinuria ≥ (++) and 24 hours total urine protein > 1.0 g.
  13. Prior chemotherapy, radiotherapy, surgery therapy within 4 weeks or palliative radiotherapy within 2 weeks or target therapy within 5 half-life of the drug before the study drug administration, or any unresolved AEs > Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.
  14. Active infection or an unexplained fever > 38.5°C within 7 days before the study drug administration, or baseline WBC>15×E+9/L .
  15. Has known history of Interstitial lung disease, or using steroids evidence of active, non-infectious pneumonitis, or would interfere with the detection and handling of suspicious drug-related pulmonary toxicity.
  16. History of immunodeficiency or human immunodeficiency virus (HIV) infection.
  17. HBV DNA>500 IU/ml,HCV RNA>1000copies/ml,HBsAg+ and anti-HCV+;
  18. Has a known additional malignancy within the last 5 years, or that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or patients with recurrent ovarian cancer has a known additional breast cancer that has been radical mastectomy and doesn't relapse within 3 years.
  19. Patients with treatment history of SHR-1210 or any other PD-L1 or PD-1 antagonists or famitinib.
  20. Patients who may receive live vaccine during the study, or previous had vaccination within 4 weeks.
  21. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's safety and participate in the study or would interfere with the interpretation of the results or lead to the trial being terminated early.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03827837

Layout table for location contacts
Contact: Quanren Wang, MD (+86) 021-50118402

Layout table for location information
China, Shanghai
Huadong Hospital Affiliated to Fudan University Recruiting
Shanghai, Shanghai, China, 200136
Contact: Director of urology         
Sponsors and Collaborators
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Principal Investigator: Dingwei Ye, MD Fudan University
Principal Investigator: Xiaohua Wu, MD Fudan University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jiangsu HengRui Medicine Co., Ltd. Identifier: NCT03827837    
Other Study ID Numbers: SHR-1210-II-213
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Uterine Cervical Neoplasms
Carcinoma, Renal Cell
Endometrial Neoplasms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Uterine Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Kidney Neoplasms
Urologic Neoplasms
Kidney Diseases
Urologic Diseases